Helicore Biopharma

#Helicore Biopharma #Monoclonal antibodies #Obesity #Phase I trial #Weight loss

First-in-class GIP antagonist for obesity enters Phase I trials

Helicore Biopharma has reported dosing the first participant in its Phase I study of HCR-188 for the treatment of obesity.   HCR-188 is a first-in-class monoclonal antibody (mAb) designed to bind to circulating glucose-dependent insulinotropic peptide (GIP) ligand, unlike antibodies that bind the GIP receptor (GIP… Read More

#News

#Financing #Helicore Biopharma #Monoclonal antibodies #Obesity #Weight loss

Obesity drug developer emerges from stealth with a $65m financing

Helicore Biopharma has announced its emergence from stealth mode with $65 million in Series A financing, co-led by founding investor Versant Ventures and by OrbiMed.  The company is focused on the discovery and development of first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions.  Helicore’s most advanced asset,… Read More

#Business & Investment #News